Qihan Fu

Shandong University — China

Biochemistry, Genetics and Molecular Biology · Life Sciences

24h-index2.6kcitations88works6.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer, Hypoxia, and Metabolism(24), Cancer Immunotherapy and Biomarkers(15), RNA modifications and cancer(14), Cancer Research and Treatments(14), Pancreatic and Hepatic Oncology Research(13)

Publications88 total

Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trials
˜The œLancet. Gastroenterology & hepatology·2025
The protein arginine methyltransferase PRMT1 ameliorates cerebral ischemia–reperfusion injury by suppressing RIPK1-mediated necroptosis and apoptosis
Acta Pharmaceutica Sinica B·2025Open Access
Safety and efficacy of a small-molecule c-Myc degrader WBC100 in solid tumors: A first-in-human, phase I trial.
Journal of Clinical Oncology·2025· 1 cited
Intraperitoneal infusion of NKG2D CAR-NK cells induces endogenous CD8+ T cell activation in patients with advanced colorectal cancer
Molecular Therapy·2025· 9 citedOpen Access
Roles of ABCA1 in Chronic Obstructive Pulmonary Disease
COPD Journal of Chronic Obstructive Pulmonary Disease·2025· 5 citedOpen Access
Prognostic value of advanced lung cancer inflammation index for upper tract urothelial carcinoma
Asian Journal of Surgery·2025Open Access
Efficacy and safety of glecirasib (JAB-21822) monotherapy and in combination with cetuximab in patients with KRAS G12C-mutated advanced colorectal cancer.
Journal of Clinical Oncology·2025· 6 cited
Comprehensive analysis of protein post-translational modifications reveals PTPN2-STAT1-AOX axis-mediated tumor progression in hepatocellular carcinomas
Translational Oncology·2025· 3 citedOpen Access
OTUD5 Protects Dopaminergic Neurons by Promoting the Degradation of α‐Synuclein in Parkinson's Disease Model
Advanced Science·2024· 2 citedOpen Access
Salivary Microbiome Relates to Neoadjuvant Immunotherapy Response in OSCC
Journal of Dental Research·2024· 15 cited
Phase I trial of hypoxia-responsive CEA CAR-T cell therapy in patients with heavily pretreated solid tumor via intraperitoneal or intravenous transfusion.
Journal of Clinical Oncology·2024· 17 cited
Phase I study of C-CAR031, a GPC3-specific TGFβRIIDN armored autologous CAR-T, in patients with advanced hepatocellular carcinoma (HCC).
Journal of Clinical Oncology·2024· 40 cited
Health research in the era of artificial intelligence: Advances in gene-editing study
Medicine Plus·2024· 9 citedOpen Access
Optimizing hepatocellular carcinoma disease staging systems by incorporating tumor micronecrosis: A multi-institutional retrospective study
Cancer Letters·2024· 4 citedOpen Access
The Landscape of Protein Post-Translational Modifications in Hepatocellular Carcinomas
SSRN Electronic Journal·2024Open Access
The Brassinosteriod Biosynthesis Enzyme Gene Ptocpd Activates Poplar Defense Against Dothiorella Gregaria Sacc Via Promoting Salicylic Acid Biosynthesis and Signaling
SSRN Electronic Journal·2024Open Access
The real-world study of the clinical characteristics, diagnosis, and treatment of advanced pancreatic cancer in China
Journal of Pancreatology·2023· 10 citedOpen Access
RUNX-3-expressing CAR T cells targeting glypican-3 in patients with heavily pretreated advanced hepatocellular carcinoma: a phase I trial
EClinicalMedicine·2023· 62 citedOpen Access
Phase I trial of chimeric anti-GPC3 scFv-CD3ε engineered T cells (CT0180) in patients with advanced hepatocellular carcinoma.
Journal of Clinical Oncology·2023· 3 cited
ASO Visual Abstract: Sintilimab Plus Modified FOLFIRINOX in Metastatic or Recurrent Pancreatic Cancer: The Randomized Phase II CISPD3 Trial
Annals of Surgical Oncology·2023
page 1 of 5Next →

Frequent Co-authors

Tingbo Liang(18), Weijia Fang(16), Yi Zheng(15), Xueli Bai(13), Lulu Liu(13), Hangyu Zhang(12), Zhou Tong(12), Xudong Zhu(11), Peng Zhao(11), Xiaomeng Dai(10), Xuanwen Bao(10), Yu Lou(9), Qida Hu(6), Jingying Zhang(6), Qi Zhang(6), Qi Zhang(5), Tingbo Liang(5), Yiwen Chen(5), Xu Sun(5), Qi Zhang(5)